Return to Listing

7 result(s) for Lung Cancers

PI Name Protocol # Title
Jeremy Cetnar STUDY00015662 CA209-451: A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) after Completion of Platinum-based First Line Chemotherapy
Jeremy Cetnar STUDY00016887 A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy
Rajan Kulkarni STUDY00017648 VAPORHCS/OHSU J: Isolation and analysis of circulating tumor cells (CTCs) and nucleic acids from patient blood specimens
Timur Mitin STUDY00018029 Prophylactic Tumor Treating Fields in Management of Patients with Small Cell Lung Cancer
Donald Sullivan STUDY00018245 VAPORHCS/OHSU J: Pilot Study of a Progressive Exercise Program Among Lung Cancer Patient-Partner Dyads (PEP-LC)
Jeremy Cetnar STUDY00019101 STUDY OF DURVALUMAB OR DURVALUMAB AND TREMELIMUMAB AS MAINTENANCE TREATMENT FOR PATIENTS WITH LIMITED STAGE SMALL-CELL LUNG CANCER WHO HAVE NOT PROGRESSED FOLLOWING CONCURRENT CHEMORADIATION THERAPY (ADRIATIC)
Christopher Ryan STUDY00019992 [NCI CIRB] MATCH - EAY131 - Molecular Analysis for Therapy Choice (MATCH)
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080